Healthcare startup funding in Australia is entering a more mature phase: overall venture investment has rebounded, healthtech now commands a larger slice of capital, and government‑backed translation funds are deliberately pushing research into commercial products. At the same time, founders face a tougher growth‑stage environment, making it vital to understand where capital is flowing and which programs and investors are active.
1. Funding landscape: healthtech’s rising share
After a post‑COVID correction, Australian startup funding bounced back in 2025—and health‑focused startups were among the standout winners.
The State of Australian Funding 2025 (summarised by Cut Through Venture and shared by Virescent Ventures) shows:
- AUD 5.1 billion invested across 390 deals in 2025, making it the third‑largest funding year on record for Australian startups.
- Healthtech (including biotech and digital health) captured 24% of all equity capital raised in 2025, up from 15% the prior year, even though its share of total deals slipped slightly.
- Funding levels in 2024 were already robust, with about AUD 4.0 billion invested—an 11% year‑on‑year increase—showing the ecosystem had “re‑found its footing” after a volatile few years.
On a regional basis, Sydney is the country’s biggest funding magnet. Startup Genome’s Sydney Startup Ecosystem report notes that New South Wales startups attracted 65% of Australia’s total startup funding in 2024, and ranks Sydney among the Top 25 most innovative cities in the world. Healthtech is one of its key strengths.
2. Digital health leads APAC – and Australia is on top
Australia is not just growing domestically; it is now a leading digital health hub in Asia–Pacific.
Galen Growth’s “Asia Pacific Digital Health 2025: Funding Shifts & Risks” finds that APAC digital health funding rose 14% in 2025 and, notably, Australia emerged as the top‑funded digital health market in the region. Key data points:
- USD 548 million deployed into Australian digital health in 2025.
- Australia ranked ahead of China (USD 520 million) and India (USD 416 million) on digital health funding volume.
- Capital is flowing into women’s health, mental health and AI‑driven diagnostics, but there is a growing “growth‑stage cash crunch” as Series B+ rounds become harder to secure.
This aligns with TechCrunch’s coverage of major healthtech deals, such as Harrison.ai’s USD 112 million Series C (about AUD 179 million) in early 2025 to scale its AI‑powered diagnostic platforms globally. Harrison.ai’s total capital raised has now reached around USD 240 million, signalling that large, late‑stage rounds are possible for top‑tier Australian healthtech companies.
3. Federal translation funds: BTF, MRFF and MTPConnect
Australia’s healthcare startup ecosystem is heavily shaped by government‑backed translation and commercialisation programs.
Biomedical Translation Fund (BTF)
The Biomedical Translation Fund (BTF) is a flagship initiative blending public and private capital. Key features:
- AUD 501.25 million in total capital—AUD 250 million from the Commonwealth and AUD 251.25 million from private investors.
- Managed by three licensed private venture fund managers that screen proposals and make equity investments.
- Targets early‑stage Australian companies commercialising biomedical discoveries, including therapeutics, medical devices and digital health technologies.
- Focuses on firms with most employees/assets in Australia and revenues under AUD 25 million at first investment.
OECD’s STIP Compass profile of the BTF explains that the fund aims to bridge the “valley of death” between research and commercial products by providing both capital and commercial expertise.
Medical Research Future Fund (MRFF) programs
The Medical Research Future Fund (MRFF) runs several initiatives that directly support health startups and translational projects:
- Biomedical Translation Bridge (BTB) initiative – provides grants to help early‑stage health and medical research reach proof‑of‑concept so that projects can attract follow‑on capital. It aims to:
- Targeted Translation Research Accelerator (TTRA) – a MRFF‑funded program focusing on diabetes and cardiovascular disease. InnovationAus reports that a recent TTRA round provides AUD 28.5 million in commercialisation funding for medtech and therapeutics, with grants of up to AUD 1.5 million per project and matched funding requirements. This round is delivered by MTPConnect in collaboration with CSL and Roche Diagnostics.
- Clinical Translation and Commercialisation Medtech (CTCM) Program – a AUD 19.75 million MRFF program delivered by MTPConnect to help high‑quality device projects progress through prototype development, product testing and early clinical evaluation. A 2025 update shared by Therapeutic Innovation Australia notes that the CTCM program has leveraged about AUD 64 million into the medtech sector, with ~75% of supported companies securing follow‑on investment.
These programs are particularly important for seed and Series A‑stage health startups that need non‑dilutive grants and validation to attract institutional VC.
4. Grants, accelerators and state‑based initiatives
Beyond MRFF and BTF, healthcare startups can tap into a growing network of accelerators and state programs.
Healthtech accelerators
- LuminaX HealthTech Accelerator Program offers up to AUD 200,000 in investment per startup, alongside a 12–14 week program based on the Gold Coast’s health precinct. Cohorts typically include digital health, medtech and biotech founders.
- LaunchVic’s HealthTech initiatives in Victoria provide grants, co‑investment and support to early‑stage healthtech and medtech startups, with dedicated programs and funds listed on its healthtech portal.
MTPConnect’s Project Fund and ecosystem support
MTPConnect—the former Medical Technologies and Pharmaceuticals Growth Centre—has historically run the Project Fund Program, a competitive matched‑funding scheme. A press release on MTPConnect’s Project Fund shows that:
- It invested AUD 7.385 million across 20 national projects in one round, with AUD 15.2 million in matched funding from industry.
- An earlier round deployed AUD 7.4 million into 14 projects, leveraging about AUD 32 million in co‑investment.
These programs help startups access specialist infrastructure (for example, Microscopy Australia), technical voucher funds and collaborative projects that make them more attractive to investors.
5. Who is funding what: investors, hubs and deal trends
Understanding the capital stack is key for founders planning a raise.
Venture and growth capital
Cut Through Venture, via its Australian VC funding data platform, tracks domestic and international VCs active in Australia. Recent healthtech rounds include:
- Harrison.ai’s USD 112 million Series C led by Aware Super, ECP Asset Management and Horizons Ventures, with participation from the National Reconstruction Fund, Ord Minnett, and existing backers.
- Multiple medtech companies supported by MTPConnect’s CTCM accelerator subsequently raising private capital—75% of CTCM‑supported startups secured follow‑on investment, according to a 2025 update.
Galen Growth notes that while early‑stage rounds remain relatively healthy, there is an emerging “growth‑stage cash crunch” across APAC digital health: it is harder to secure large Series B/C rounds without strong revenue traction and clear paths to profitability.
Ecosystem hubs
Startup Genome’s Sydney ecosystem report emphasises that Sydney has a strong base of biotech, medtech and healthtech companies, supported by universities and major hospitals. Melbourne similarly benefits from major research institutions and global pharma/medtech presences, making both cities prime locations for health startup headquarters and clinical pilots.
6. Practical routes to funding for Australian healthcare startups
For founders, the funding journey typically involves a mix of grants, accelerators, angel/seed capital, and later VC or BTF‑style growth capital.
A typical pathway might look like:
- Idea & proof‑of‑concept
- Apply for MRFF grants like the Biomedical Translation Bridge (BTB) or state‑based programs (for example, LaunchVic) to move from lab results to prototypes.
- Join accelerators such as LuminaX for mentoring, initial capital and industry connections.
- Clinical validation & regulatory pathway
- Seed and Series A
- Leverage non‑dilutive funding and early data to attract seed/Series A investors listed in Cut Through Venture’s funding reports.
- Target VCs and corporate venture arms with a focus on health, deep tech or impact.
- Scaling & global expansion
- Engage with BTF fund managers—as described on Bulletpoint’s BTF explainer and gemaker’s BTF overview—for larger equity rounds and strategic support.
- Use case studies like Aravax’s BTF investment as a template for aligning milestones and co‑investment strategies.
7. Strategic considerations for founders and investors
Given this environment, both startups and investors need to think strategically about stage, capital mix and validation:
- Plan for longer runways. With growth‑stage funding tighter, founders should aim for longer cash runways and clear milestones between rounds, making heavy use of MRFF and state grants in the early years.
- Use translation programs to derisk. BTF, BTB, TTRA and CTCM are designed to de‑risk clinical and regulatory milestones, making companies more attractive to VC.
- Build evidence early. Programs like CTCM emphasise robust clinical and economic evidence; companies that hit these marks are more likely to secure follow‑on funding (as the 75% follow‑on rate suggests).
- Think globally from day one. With Australia now the top APAC digital health funding destination, there is a clear opportunity to build regionally focused platforms out of Australia, but investors will still expect a global TAM (especially in the US and EU).
- Leverage ecosystem partners. Universities, hospital networks, MTPConnect programs and accelerators like LuminaX or LaunchVic‑funded initiatives are crucial for pilots, data access and credibility.